Red Arrow Therapeutics is a biotech firm that provides systemic cytokine delivery, targeted intratumoral activation, and biological potency.
Red Arrow Therapeutics has raised $55.0M in total funding. The most recent round was Series A. The last funding was announced in September 2024.
Red Arrow Therapeutics's investors include UTEC - The University of Tokyo Edge Capital Partners, Beyond Next Ventures, Cure Ventures, Third Rock Ventures, SkyDeck Berkeley.
Red Arrow Therapeutics is headquartered in Minato, Japan.
Red Arrow Therapeutics is a biotech firm that provides systemic cytokine delivery, targeted intratumoral activation, and biological potency.
Red Arrow Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Red Arrow Therapeutics — Funding & Investors." VCBacked, September 18, 2024, https://www.vcbacked.co/company/red-arrow-therapeutics. Accessed August 13, 2026.
VCBacked. (2024). Red Arrow Therapeutics — Funding & Investors. Retrieved August 13, 2026, from https://www.vcbacked.co/company/red-arrow-therapeutics
{{cite web |title=Red Arrow Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/red-arrow-therapeutics |website=VCBacked |access-date=August 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated